Gilead’s (NASDAQ:GILD) treatment for coronavirus “could be approved for Covid-19 very soon,” a Piper Sandler analyst says.
“We now believe the remdesivir clinical trial
results are likely to be positive,” analyst Tyler Van Buren says of
GILD’s experimental medicine.
“If successful, it could be approved for broad use
in the coming months considering it’s safe, the bar for efficacy in the
context of the ongoing global pandemic is low.”
GILD +9.4% today.
https://seekingalpha.com/news/3553075-gileads-covidminus-19-drug-may-get-quick-fda-approval
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.